Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1405873 | 0.83 | CYP1A2 (0.38) | CYP1A2TSHRHPGDKMT2AGPR3 | |
| SCHEMBL30510259 | 0.83 | CYP1A2 (0.38) | CYP1A2TSHRHPGDKMT2AGPR3 | |
| SCHEMBL4599750 | 0.83 | CYP1A2 (0.38) | CYP1A2TSHRHPGDKMT2AGPR3 | |
| SCHEMBL1405820 | 0.83 | CYP1A2 (0.38) | CYP1A2TSHRHPGDKMT2AGPR3 | |
| SCHEMBL1120764 | 0.82 | KEAP1 (0.35) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL6389450 | 0.82 | KIF11 (0.39) | KIF11 | |
| SCHEMBL8812896 | 0.82 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL418100 | 0.82 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL5497625 | 0.82 | CYP1A2 (0.47) | CYP1A2TSHRKMT2AGPR3POLB | |
| SCHEMBL30510335 | 0.82 | CYP1A2 (0.38) | CYP1A2TSHRKMT2AGPR3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-1879895-B1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | CYP1A2 1309/4885TSHR 3751/4885KIF11 3351/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | CYP1A2 643/4885TSHR 894/4885KIF11 4779/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | CYP1A2 775/4885TSHR 1357/4885KIF11 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.